Nanomedicine for Blood Cancer developed
The Kochi-based Amrita Centre for Nanosciences and Molecular Medicine has developed a nano-medicine for drug-resistant blood cancer. This invention expected to significantly improve the treatment of drug-resistant Chronic Myelogenous Leukemia (CML), when used in combination with Imatinib, the standard drug for the disease.
In another major invention, the institute has developed a mechanism that can efficaciously prevent recurrence of glioma or brain tumour. This disease affects about 4 out of every 100000 people in India.
What is Chronic Myelogenous Leukemia?
Chronic Myelogenous Leukemia is a form of blood cancer which affects around 2 out of every 100000 Indians annually.